4397-14-2

Basic information

• Product Name: 3,5-Dimethyl-4-hydroxybenzenemethanol
• Synonyms: 3,5-Dimethyl-4-hydroxybenzenemethanol;4-Hydroxy-3,5-dimethylbenzenemethanol;4-Hydroxy-3,5-dimethylbenzyl alcohol;2,6-dimethyl-4-methylol-phenol
• CAS NO: 4397-14-2
• Molecular Formula: C₉H₁₂O₂
• Molecular Weight: 152.19
• Mol File: 4397-14-2.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 293.8°C at 760 mmHg
• Flash Point: 143.5°C
• Appearance: /
• Density: 1.133g/cm³
• Vapor Pressure: 0.000766mmHg at 25°C
• Refractive Index: 1.573
• CAS DataBase Reference: 3,5-Dimethyl-4-hydroxybenzenemethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Dimethyl-4-hydroxybenzenemethanol(4397-14-2)
• EPA Substance Registry System: 3,5-Dimethyl-4-hydroxybenzenemethanol(4397-14-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 4397-14-2(Hazardous Substances Data)

Usage

General Description

3,5-Dimethyl-4-hydroxybenzenemethanol, also known as 3,5-xylenol, is a chemical compound with the molecular formula C9H12O2. 3,5-Dimethyl-4-hydroxybenzenemethanol belongs to the class of phenolic compounds and is commonly used as an intermediate in the production of various industrial chemicals, including antioxidants, plasticizers, and fragrances. It is a colorless to pale yellow liquid with a characteristic phenolic odor, and it is soluble in organic solvents but insoluble in water. 3,5-xylenol is also used as a preservative in personal care products and as an antimicrobial agent in industrial applications. However, it is important to handle this chemical with care, as it can be harmful if ingested, inhaled, or absorbed through the skin.

InChI:InChI=1/C9H12O2/c1-6-3-8(5-10)4-7(2)9(6)11/h3-4,10-11H,5H2,1-2H3

Upstream product

• 527-60-6 Mesitol 
• 2233-18-3 4-hydroxy-3,5-dimethylbenzaldehyde 
• 83037-97-2 4-hydroxy-3,5-dimethylbenzyltrimethylammonium iodide 
• 576-26-1 2.6-dimethylphenol 
• 87-62-7 2,6-dimethylaniline 
• 4919-37-3 3,5-dimethyl-4-hydroxybenzoic acid 
• 34137-14-9 methyl 4-hydroxy-3,5-dimethylbenzoate 
• 36197-06-5 2,6-dimethyl-p-quinone methide 
• 32288-01-0 dibutyl phosphate anion 
• 47017-75-4 dibenzyl phosphate 
• 48042-47-3 diethyl phosphate 
• 50-00-0 formaldehyd 

Downstream Products

• 30128-02-0 2,6-dimethyl-[1,4]benzoquinone-4-(4-hydroxy-phenylimine) 
• 527-60-6 Mesitol 
• 2233-18-3 4-hydroxy-3,5-dimethylbenzaldehyde 
• 25347-59-5 3,5,3',5'-tetramethyl-stilbene-4,4'-diol 
• 6476-26-2 4,4’-(ethane-1,2-diyl)bis(2,6-dimethylphenol) 
• 5384-21-4 bis(4-hydroxy-3,5-dimethylphenyl)methane 
• 527-61-7 2,6-dimethyl-1,4-benzoquinone 
• 4103-68-8 bis-(4-hydroxy-3,5-dimethyl-benzyl)-sulfide 
• 45952-56-5 3,5-dimethyl-4-hydroxybenzyl bromide 
• 71655-87-3 4,4'-(oxybis(methylene))bis(2,6-dimethylphenol) 
• 50-00-0 formaldehyd 
• 43109-10-0 2,6-dimethyl-4-[(E)-(2,4-dinitrophenyl)diazenyl]phenol 
• 36197-06-5 2,6-dimethyl-p-quinone methide 
• 4276-69-1 4,3'-Dihydroxy-3,5,2',4',6'-pentamethyl-diphenylmethan 

Relevant articles and documents

Unusual transformation of 4-hydroxy/methoxybenzylic alcohols via C[sbnd]C ipso-substitution reaction using proton-exchanged montmorillonite as media

We present here proton-exchanged montmorillonite-mediated an unusual transformation of 4-hydroxy and 4-methoxybenzylic alcohols to form symmetrical benzylic ethers and diarylmethanes under mild conditions. Nuclear magnetic resonance spectroscopy and density functional theory calculations support a plausible mechanism, which includes a distinctive aromatic C[sbnd]C ipso-substitution reaction with a hydroxymethyl group as the C-based leaving group.

LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.